Search

Your search keyword '"Monique L. Den Boer"' showing total 222 results

Search Constraints

Start Over You searched for: Author "Monique L. Den Boer" Remove constraint Author: "Monique L. Den Boer"
222 results on '"Monique L. Den Boer"'

Search Results

1. Cyclin C promotes development and progression of B-cell acute lymphoblastic leukemia by counteracting p53-mediated stress responses

2. Targeted treatment options for paediatric B-cell precursor acute lymphoblastic leukaemia patients with constitutional or somatic chromosome 21 alterations

3. B-cell precursor acute lymphoblastic leukemia elicits an interferon-α/β response in bone marrow-derived mesenchymal stroma

6. PB1725: INTERNATIONAL LEUKEMIA TARGET BOARD - A PLATFORM TO DISCUSS AND PRIORITIZE TARGETED TREATMENT OPTIONS FOR PATIENTS WITH RELAPSED/REFRACTORY PEDIATRIC HEMATOLOGICAL MALIGNANCIES (ILTB) – ITCC 107

7. The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia

9. Integrating copy number data of 64 iAMP21 BCP-ALL patients narrows the common region of amplification to 1.57 Mb

10. Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity

11. Ibrutinib is not an effective drug in primografts of TCF3-PBX1

12. Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?

14. Autophagy inhibition as a potential future targeted therapy for ETV6-RUNX1-driven B-cell precursor acute lymphoblastic leukemia

17. Tunneling Nanotubes and Gap Junctions–Their Role in Long-Range Intercellular Communication during Development, Health, and Disease Conditions

18. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients

20. Acute B lymphoblastic leukaemia‐propagating cells are present at high frequency in diverse lymphoblast populations

25. The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance

26. Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells

27. The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97)

28. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia

29. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia

30. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia

31. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia

32. Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia

33. Various Cell Types in the Bone Marrow sustain Primary B-Cell Precursor Acute Lymphoblastic Leukemia

34. B-Cell Precursor Acute Lymphoblastic Leukemia elicits an Interferon-α/β response in Bone Marrow-derived Mesenchymal Stroma

35. Data from Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia

36. Supplementary Tables from Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia

37. Supplementary Figures, and Supplementary Table Legends from Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia

38. Supplementary Figures 1-4 from Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening

39. Supplementary Table 7 from Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening

40. Supplementary Table 4 from Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening

41. Supplementary Table 1 from Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening

42. Supplementary Table 3 from Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening

43. Supplementary Tables 1-3 from Gene Expression Profiling Identifies BAX-δ as a Novel Tumor Antigen in Acute Lymphoblastic Leukemia

44. Supplementary Table 6 from Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening

45. Sweave Document from Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening

46. Supplementary Table 2 from Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening

47. Supplementary Legends for Tables 1-4 and Figures 1-7 from Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening

48. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia

49. Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions

50. Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia

Catalog

Books, media, physical & digital resources